{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:56:30Z","timestamp":1790142990887,"version":"4.0.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["86-004-26"],"award-info":[{"award-number":["86-004-26"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research and Education Program Fund","award":["KL2TR001438"],"award-info":[{"award-number":["KL2TR001438"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/Background:<\/jats:title>\n                    <jats:p>\n                      To assess abnormalities found on CD138-enriched fluorescent\n                      <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                      hybridization (FISH) studies on pre-treatment bone marrow in systemic amyloid light-chain amyloidosis (AL) and correlate findings between these abnormalities with organ involvement and 1-year survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We reviewed 107 patients with systemic AL to identify the impact of a diagnostic FISH study done on plasma cell-enriched bone marrow in our institution between January 2010 and January 2015; 77 had pre-treatment testing performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 77 (61%) patients had abnormal FISH including: hyperdiploidy (29%), t(11;14), (20%), hypodiploidy (16%), t(4;14), (1%), del17p (5%), and + 1q21 (5%). Abnormal FISH studies were more likely in those patients with plasma cell involvement \u2265 10% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .002). FISH abnormalities were not shown to correlate with stage, cardiac involvement, or survival at 1 year. One-year survival was significantly affected by stage at diagnosis and presence of cardiac and hepatic amyloid involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T14:00:26Z","timestamp":1502892026000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis"],"prefix":"10.4103","volume":"11","author":[{"given":"Lindsay","family":"Hammons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.07.005_b0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ajh.23828","article-title":"Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment","volume":"89","author":"Gertz","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2017.07.005_b0010","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.07.005_b0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.07.005_b0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2141.2002.03438.x","article-title":"Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis","volume":"117","author":"Harrison","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.07.005_b0025","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/bcj.2015.34","article-title":"Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death","volume":"5","author":"Warsame","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hemonc.2017.07.005_b0030","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.07.005_b0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2012.03.001","article-title":"What do I need to know about immunoglobulin light chain (AL) amyloidosis?","volume":"26","author":"Dispenzieri","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.hemonc.2017.07.005_b0040","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.07.005_b0045","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.07.005_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2016.03.001","article-title":"Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance","volume":"44","author":"Kim","year":"2016","journal-title":"Leukemia Res"},{"key":"10.1016\/j.hemonc.2017.07.005_b0055","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V98.7.2266","article-title":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis","volume":"98","author":"Hayman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.07.005_b0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.07.005_b0065","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.07.005_b0070","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1038\/bcj.2014.91","article-title":"Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study","volume":"5","author":"Greenberg","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hemonc.2017.07.005_b0075","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)","volume":"117","author":"Bochtler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.07.005_b0080","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood.V116.21.1197.1197","article-title":"FISH reveals chromosomal abnormalities in 41 patients with systemic amyloidosis (AL)","volume":"116","author":"Bernasconi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.07.005_b0085","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2007-11-122101","article-title":"Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability","volume":"111","author":"Bochtler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.07.005_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler","year":"2014","journal-title":"Amyloid"},{"key":"10.1016\/j.hemonc.2017.07.005_b0095","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201811020-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:34Z","timestamp":1787838574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201811020-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.07.005","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}